OakChart

ArriVent BioPharma Inc

AVBPHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

13.51+0.02 (0.11%)
2026-11-11 23:11 CET
Market cap
665.16 USD m
Revenue, TTM
5.00 USD m
Net income, TTM
-169.07 USD m
Free cash flow, TTM
-152.84 USD m
EPS diluted, TTM
-3.66
P/E
-
Compare

Price

AVBP against its 20, 50 and 200-day averages
2050200beatmiss
10.0020.0030.009.9M19.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AVBPclose 13.5120-day 15.6950-day 22.07200-day 26.5713.5152w high52w low

62.3% under the 52-week high of 35.83 on 26 Jun 2026. 52-week low 11.36 on 6 Oct 2026. Last 15 sessions, 76.9% high to low

Volume 0.72× normal · the line is the 50-bar volume average

Profile

AVBP
52-week range, 9% of the way up
11.3635.83

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

IndexRUT
Employees77
IPOJan 26, 2024
Beta1.69
ATR, 14d1.60
Rel volume0.72
Short float15.67%
Insider own24.95%
Inst own78.99%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap698.52M
Enterprise Value305.56M
Income-169.07M
Sales5.00M
Book/sh7.68
Cash/sh7.60
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees77
IPOJan 26, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S139.70
P/B1.76
P/C1.78
P/FCF-
EV/EBITDA-
EV/Sales61.11
Quick Ratio17.64
Current Ratio17.64
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.66
EPS next Y-3.68
EPS next Q-1.01
EPS this Y8.77%
EPS next Y6.62%
EPS next 5Y12.49%
EPS past 3/5Y-57.73% -29.43%
Sales past 3/5Y- -
EPS Y/Y TTM13.57%
Sales Y/Y TTM-
EPS Q/Q2.46%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.22.55% -

Ownership

Insider Own24.95%
Insider Trans0.00%
Inst Own78.99%
Inst Trans6.03%
ROA-45.47%
ROE-48.41%
ROIC-42.97%
Gross Margin0.00%
Oper. Margin-3620.02%
Profit Margin-3381.40%
SMA20-13.91%
SMA50-38.80%
SMA200-49.18%
Trades-

Technical

Shs Outstand51.21M
Shs Float37.00M
Short Float15.67%
Short Ratio4.56
Short Interest5.80M
52W High35.83 -62.31%
52W Low11.36 18.88%
Volatility11.49% 9.20%
ATR (14)1.60
RSI (14)35.52
Beta1.69
Rel Volume0.72
Avg Volume1.27M
Volume910,982

Performance

Perf Week0.11%
Perf Month-16.07%
Perf Quarter-54.98%
Perf Half Y-53.32%
Perf YTD-32.88%
Perf Year-30.31%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price26.00
Prev Close13.49
Price13.51
Change %0.11%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Mar 12, 2026ResumedBBTIG ResearchBuy$42+211.0%
Dec 10, 2025InitiatedBBTIG ResearchBuy$45+233.2%
Nov 25, 2025InitiatedTTruistBuy$43+218.4%
Jul 10, 2025ResumedGGoldmanBuy$33+144.4%
Mar 20, 2025InitiatedRB. Riley SecuritiesBuy$37+174.0%
Mar 10, 2025InitiatedGGuggenheimBuy$45+233.2%
Jul 22, 2024InitiatedOOppenheimerOutperform$35+159.2%
Apr 30, 2024InitiatedHH.C. WainwrightBuy$25+85.1%
Feb 20, 2024InitiatedJJefferiesBuy$35+159.2%
Feb 20, 2024InitiatedGGoldmanBuy$27+99.9%

Peers

Mkt cap
TickerCompanyMkt cap
CGEMCullinan Therapeutics Inc730.42M
NUVBNuvation Bio Inc1.52B
BLSMBlossomHill Therapeutics Inc512.38M
BDTXBlack Diamond Therapeutics Inc92.50M
ORICORIC Pharmaceuticals Inc932.88M
TYRATyra Biosciences Inc1.44B
ELVNEnliven Therapeutics Inc3.77B
ERASErasca Inc5.88B
SMMTSummit Therapeutics Inc13.27B
OKUROnKure Therapeutics Inc136.09M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
LaChapelle RobinChief Operating OfficerOct 30 '26Option Exercise4.5440,693184,897176,429Nov 02 04:47 PM
HILLHOUSE INVESTMENT MANAGEMEN10% OwnerDec 10 '25Sale23.37555,55512,983,3203,929,117Feb 03 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 114

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.810-1.046-0.8105.000.0011
2026Q22026-08-12-1.050-0.987-1.0480.000.0011
2026Q12026-05-11-0.960-0.895-0.9610.000.0011
2025Q42026-03-05-0.840-0.846-0.8370.000.0012
2025Q32025-11-10-0.830-0.789-0.8350.000.0010
2025Q22025-08-11-0.900-0.712-0.8970.000.009
2025Q12025-05-12-1.900-0.664-1.8910.00-5
2024Q42025-03-03-0.600-0.665-0.6120.000.005
2024Q32024-11-14-0.610-1.003-0.6100.000.006
2024Q22024-08-14-0.650-0.644-0.6530.000.006
2024Q12024-05-08-0.700-1.077-0.5200.000.004
2023Q42024-03-28-5.300-0.650-0.6330.000.001
2026Q4---1.010--0.0011
2027Q1---0.945--3.056
2027Q2---0.975--3.056
2027Q3---0.983--3.056

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-32.380-8.541-2.0700.00-1.67
2024FY-2.560-2.580-2.3880.000.00
2025FY-4.320-4.410-4.3200.000.00
2026FY--3.941--3.64
2027FY--3.680--6.74
2028FY--2.895--30.41
2029FY--2.053--104.64
2030FY--0.433--234.84

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-109000.000.000.00
2026Q4S2026-11-099000.000.000.00
2026Q4S2026-10-149000.000.000.00
2026Q4S2026-10-068000.000.000.00
2026Q4S2026-10-059000.000.000.00
2026Q4S2026-09-208000.000.000.00
2026Q4S2026-08-149000.000.000.00
2026Q4S2026-08-138000.000.000.00
2026Q4S2026-07-218000.000.000.00
2026Q4S2026-05-279000.000.000.00
2026Q4S2026-05-128000.000.000.00
2026Q4S2026-04-248000.000.000.00
2026Q4S2026-03-107000.000.000.00
2026Q4S2026-03-066000.000.000.00

Estimate history

EPS, annual-1.541-1.102-2.07-2.388-4.324-3.6605
Period20212022202320242025TTM
EPS, quarterly-0.61-0.612-1.891-0.897-0.835-0.837-0.961-1.048-0.814
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000005
Period20212022202320242025TTM
Sales, quarterly000000005
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual33.49433.49433.49433.70742.45251.212
Period20212022202320242025MRQ
Shares, quarterly33.69433.70734.04137.4940.85242.45245.30948.3251.212
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue5.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A-0.000.000.000.000.00
Gross Profit-0.000.000.000.000.00
Selling, General and Administrative Excl. Other186.00177.5394.3174.5936.918.70
Research and Development151.03153.3579.0064.8830.436.43
Other Operating Expense0.000.000.000.000.000.00
Operating Income-181.00-177.53-94.31-74.59-36.91-8.70
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.0042.91
Net Income Before Taxes-169.07-166.31-80.49-69.33-36.91-51.61
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-169.07-166.31-80.49-69.33-36.91-51.61
Net Income From Continuing Operations-169.07-166.31-80.49-69.33-36.91-51.61
Net Income-169.07-166.31-80.49-69.33-36.91-51.61
EPS (Recurring)-3.41-4.32-2.39-2.07-1.10-0.64
EPS (Basic, Before Extraordinaries)-3.66-4.32-2.39-2.07-1.10-1.54
EPS (Diluted)-3.66-4.32-2.39-2.07-1.10-1.54
EBITDA-181.00-177.53-94.31-74.59-36.91-8.70
Non-Operating Income (Expense)11.9311.2313.825.260.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense22.2612.523.210.900.420.05
Price To Sales Ratio299.93-----
Operating Margin-3,620.02-----
Net Margin-3,381.40-----
Shares Outstanding51.2142.4533.7133.4933.4933.49
Market Capitalization665.16665.16897.69908.14--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue5.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A-0.000.000.000.000.000.000.00
Gross Profit-0.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other48.3852.6946.1138.8238.3233.6266.7723.70
Research and Development38.9042.3437.6232.1732.1727.7261.2920.16
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-43.38-52.69-46.11-38.82-38.32-33.62-66.77-23.70
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-40.31-49.89-43.32-35.54-34.98-31.40-64.39-20.63
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-40.31-49.89-43.32-35.54-34.98-31.40-64.39-20.63
Net Income From Continuing Operations-40.31-49.89-43.32-35.54-34.98-31.40-64.39-20.63
Net Income-40.31-49.89-43.32-35.54-34.98-31.40-64.39-20.63
EPS (Recurring)-0.81-1.05-0.96-0.84-0.83-0.90-1.89-0.61
EPS (Basic, Before Extraordinaries)-0.81-1.05-0.96-0.84-0.83-0.90-1.89-0.61
EPS (Diluted)-0.81-1.05-0.96-0.84-0.83-0.90-1.89-0.61
EBITDA-43.38-52.69-46.11-38.82-38.32-33.62-66.77-23.70
Non-Operating Income (Expense)3.062.802.793.283.342.222.383.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.886.675.493.223.723.312.270.95
Price To Sales Ratio299.93-------
Operating Margin-867.52-------
Net Margin-806.26-------
Shares Outstanding51.2148.3245.3142.4540.8537.4934.0433.71
Market Capitalization665.161,618.011,019.73830.58748.50744.81628.96897.69

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments312.82218.86150.39163.3737.28
Short Term Receivables0.000.500.760.500.25
Inventories0.000.000.000.000.00
Other Current Assets20.087.628.8218.755.42
Total Current Assets332.90226.98159.97182.6242.95
Net Property, Plant & Equipment0.010.150.290.140.00
Total Investments and Advances0.0047.680.000.000.00
Long-Term Note Receivable---0.000.00
Intangible Assets--0.00--
Other Assets0.260.132.840.070.09
Total Assets333.17274.94163.10182.8343.04
Short Term Debt Incl. Current Port. of LT Debt0.010.160.140.130.00
Accounts Payable5.933.784.533.090.29
Other Current Liabilities20.0013.336.955.141.52
Total Current Liabilities25.9517.2711.628.361.82
Long Term Debt0.000.010.180.010.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.000.00
Total Liabilities25.9517.2911.808.371.82
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00304.49259.5789.86
Common Equity307.22257.65-153.19-85.11-48.64
Total Shareholders Equity307.22257.65151.30174.4641.22
Accumulated Minority Interest0.000.000.000.000.00
Total Equity307.22257.65151.30174.4641.22
Total Liabilities & Stockholders Equity333.17274.94163.10182.8343.04
Book Value Per Share7.247.64-4.57-2.54-1.45
Tangible Book Value Per Share7.247.64-4.57-2.54-1.45
Full-Time Employees775240--
Price to Book Ratio1.763.233.27--
Return on Assets-54.70-36.75-40.08-32.68-
Return on Equity-58.88-39.36-42.57-34.22-
Return on Invested Capital-54.13-31.24-45.77-21.15-125.19
Quick Ratio12.8313.1413.7621.8423.63
Current Ratio12.8313.1413.7621.8423.63

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-169.07-166.31-80.49-69.33-36.91-51.61
Other Funds (Non Cash)17.509.493.210.900.4242.96
Funds from Operations-151.57-156.81-77.28-68.44-36.48-8.65
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.27-3.777.0712.60-7.15-3.94
Cash from Operating Activities-152.84-160.59-70.21-55.84-43.63-12.59
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-82.20-71.23-192.470.000.000.00
Purchase of Investments-355.78-272.93-194.16-25.000.000.00
Sale Or Maturity of Investments273.58201.711.7025.000.000.00
Other Uses0.000.000.000.000.00-40.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-82.20-71.23-192.470.000.00-40.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock236.02203.13186.5842.86169.7289.87
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock236.02203.13186.5842.86169.7289.87
Proceedsfrom Stock Options234.33202.63185.9542.51169.7189.87
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.07-0.070.000.000.000.00
Other Financing Activities Uses-0.07-0.070.000.000.000.00
Cash from Financing Activities235.95203.06186.5842.86169.7289.87
Net Change in Cash0.91-28.75-76.10-12.98126.0937.28
Free Cash Flow-152.84-160.59-70.21-55.84-43.63-12.59
Preferred Dividends (Cash Flow)-0.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments393.22373.12326.38312.82300.27235.69
Short Term Receivables0.000.000.000.000.510.51
Inventories0.000.000.000.000.000.00
Other Current Assets23.3921.0522.3220.0820.4513.96
Total Current Assets416.62394.17348.70332.90321.22250.15
Net Property, Plant & Equipment0.300.370.370.010.050.09
Total Investments and Advances0.000.000.000.005.1118.79
Other Assets0.170.170.230.260.180.48
Total Assets417.09394.72349.30333.17326.56269.51
Short Term Debt Incl. Current Port. of LT Debt0.260.320.100.010.060.10
Accounts Payable2.622.228.735.935.934.06
Other Current Liabilities20.7425.3116.1720.0015.5715.48
Total Current Liabilities23.6127.8425.0025.9521.5619.64
Long Term Debt0.000.030.320.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities23.6127.8825.3225.9521.5619.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity393.48366.84323.98307.22305.00249.87
Total Shareholders Equity393.48366.84323.98307.22305.00249.87
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity393.48366.84323.98307.22305.00249.87
Total Liabilities & Stockholders Equity417.09394.72349.30333.17326.56269.51
Book Value Per Share7.687.597.157.247.476.66
Tangible Book Value Per Share7.687.597.157.247.476.66
Full-Time Employees---77--
Price to Book Ratio1.764.863.192.692.773.66
Return on Assets-45.47-49.30-51.43-54.70-48.90-47.37
Return on Equity-48.41-53.10-55.17-58.88-51.98-50.13
Return on Invested Capital-10.25-13.60-13.36-11.57-11.47-12.57
Quick Ratio17.6414.1613.9512.8314.9012.74
Current Ratio17.6414.1613.9512.8314.9012.74

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-40.31-49.89-43.32-35.54-34.98-31.40
Other Funds (Non Cash)6.236.154.930.203.723.31
Funds from Operations-34.08-43.74-38.39-35.35-31.26-28.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.634.16-3.504.69-4.541.96
Cash from Operating Activities-40.71-39.58-41.89-30.66-35.80-26.12
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-60.6546.073.58-71.20-50.7613.91
Purchase of Investments-126.22-13.99-64.38-151.18-90.37-21.57
Sale Or Maturity of Investments65.5760.0667.9779.9839.6135.48
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-60.6546.073.58-71.20-50.7613.91
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock60.2686.0954.8734.8086.4775.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock60.2686.0954.8734.8086.4775.11
Proceedsfrom Stock Options59.6685.2354.7234.7186.4275.04
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.070.000.00
Other Financing Activities Uses0.000.000.00-0.070.000.00
Cash from Financing Activities60.2686.0954.8734.7386.4775.11
Net Change in Cash-41.1092.5816.56-67.13-0.0962.90
Free Cash Flow-40.71-39.58-41.89-30.66-35.80-26.12

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.67%5.8M37.0M1.18M
2026-10-1518.40%6.8M37.0M988.00K
2026-09-3024.40%8.5M34.6M520.37K
2026-09-1525.31%8.8M34.6M530.59K
2026-08-3125.09%8.7M34.6M548.32K
2026-08-1423.75%8.2M34.6M563.51K
2026-07-3124.11%8.0M33.4M555.80K
2026-07-1522.97%7.7M33.4M541.39K
2026-06-3022.85%7.6M33.4M556.36K
2026-06-1523.52%7.8M33.4M489.22K
2026-05-2923.61%7.7M32.7M516.22K
2026-05-1523.86%7.3M30.6M483.28K
2026-04-3022.66%7.1M31.4M532.77K
2026-04-1525.62%7.7M29.9M522.01K
2026-03-3126.86%7.8M28.9M499.84K
2026-03-1325.00%7.2M28.9M507.71K
2026-02-2724.23%7.0M28.9M447.76K
2026-02-1326.10%7.0M27.0M445.27K
2026-01-3027.44%7.2M26.3M401.92K
2026-01-1527.30%7.2M26.3M381.15K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.509.1013.100.0022.2810.000.000.991-0.0170.001
call5.006.6010.600.0011.0740.000.000.984-0.0170.001
call7.504.108.100.007.3530.000.000.974-0.0160.001
call10.001.605.600.005.0160.000.000.833-0.0780.005
call12.500.254.600.005.1830.000.000.655-0.1030.008
call15.000.051.200.622.09755.000.000.439-0.0990.008
call17.500.000.450.201.8582031900.227-0.0670.006
call20.000.000.400.052.2923,3621020.179-0.0720.005
call22.500.000.200.302.26118.000.000.102-0.0480.004
call25.000.004.600.202.5842.000.000.092-0.0510.003
call30.000.000.050.102.98592.000.000.080-0.0540.003
call35.000.004.600.052.81810.000.000.026-0.0200.001
call40.000.004.600.053.12911.000.000.024-0.0210.001
put2.500.000.050.005.3670.000.00-0.009-0.0150.001
put5.000.001.500.003.4000.000.00-0.016-0.0160.001
put7.500.000.050.054.47424.000.00-0.113-0.1020.004
put10.000.000.850.252.58878.000.00-0.167-0.0770.005
put12.500.051.100.801.9405680.00-0.345-0.1020.008
put15.000.354.602.404.4055380.00-0.561-0.0970.008
put17.502.206.105.104.0241970.00-0.773-0.0650.006
put20.004.408.407.004.56616.000.00-0.807-0.0730.006
put22.506.9010.906.405.07118.000.00-0.898-0.0440.004
put25.009.4013.405.255.49684.000.00-0.908-0.0470.004
put30.0014.4018.406.506.18435.000.00-0.971-0.0150.001
put35.0019.4023.400.006.7300.000.00-0.974-0.0160.001
put40.0024.4028.400.007.1810.000.00-0.976-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-06SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-10-268-KCurrent report2026-10-25SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-13SCHEDULE 13GSEC
2026-10-138-KCurrent report2026-10-12SEC
2026-10-08SCHEDULE 13D/ASEC
2026-10-068-KCurrent report2026-10-06SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-11SEC
2026-07-27SCHEDULE 13G/ASEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-05-11424B5SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-05-06SCHEDULE 13G/ASEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-03-178-KCurrent report2026-03-17SEC
2026-03-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-0510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-058-KCurrent report2026-03-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120012.98M1
2025-110000

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC9.70%
INFINITUM ASSET MANAGEMENT, LLC9.53%
HHLR ADVISORS, LTD.8.44%
BlackRock, Inc.6.98%
ORBIMED ADVISORS LLC6.50%
FMR LLC6.02%
Octagon Capital Advisors LP4.23%
VANGUARD CAPITAL MANAGEMENT LLC3.81%
Sofinnova Investments, Inc.3.64%
STATE STREET CORP3.63%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.87%
Select Biotechnology Portfolio2.68%
iShares Russell 2000 ETF2.11%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.89%
Fidelity Small Cap Index Fund0.89%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
iShares Russell 2000 Growth ETF0.75%
Fidelity Growth Company Fund0.66%
Fidelity Small Cap Growth Fund0.64%
iShares Biotechnology ETF0.49%

OakChart. AVBP. Cached 15 minutes.